Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Breast Cancer
•
Medical Oncology
•
HR+
•
Breast Cancer, Non-metastatic
Would you treat beyond 10 years of adjuvant hormonal therapy for premenopausal woman with high risk ER+ HER2 negative breast cancer who remain premenopausal at the end of 10 year adjuvant hormonal therapy?
What factors may influence your decision making?
Related Questions
For pre or perimenopausal women with early stage, hormone positive breast cancer who refuse to stop HRT (for severe perimenopausal symptoms - severe depression/anxiety/very low energy/vaginal dryness and pain with sex that's failed vaginal estrogen therapy), do you still recommend Tamoxifen or other endocrine therapy in addition to the HRT that is being taken?
Which chemotherapy is preferred between TC and AC-T in a young patient with ER+/PR+/HER2- node negative breast cancer, intermediate grade, with high OncoType score?
How would you decide the duration of ovarian suppression in premenopausal females with early stage ER+ breast cancer?
Do you have concerns about the generalizability of Oncotype testing/Mammaprint testing in making chemotherapy decisions for non-Caucasian women?
Is any hormonal monitoring necessary for males with breast cancer on adjuvant aromatase inhibitor and LHRH agonist (Lupron)?
How do you approach ovarian function suppression in premenopausal women with HR+/HER2-, node negative breast cancer and intermediate OncoType dx scores (11-25) who received chemotherapy?
What adjuvant systemic therapy would you give a patient with pN2 nodal relapse of ER+/HER2- breast cancer now s/p ALND, after initial mastectomy, adjuvant TC, and 5 years of endocrine therapy?
Would you recommend adjuvant endocrine therapy in combination with immunotherapy for triple negative metaplastic breast cancer with residual disease that is ER strongly positive?
Would you avoid chemotherapy in a postmenopausal woman age >65 with T3 HR+/HER2 negative with Oncotype DX < 25?
How would you approach adjuvant therapy for large (≥4 cm), node negative, HR+, HER2- breast cancer in an elderly woman with comorbidities including neuropathy?